D.E. Shaw & Co’s Argos Therapeutics, Inc. ARGS Stock Holding History

D.E. Shaw & Co’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,995	Closed	-$196K	–	3823
2016 Q4	$196K	Buy	+1,995	New	+$187K	﹤0.01%	3271

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

D.E. Shaw & Co's ARGS Position: Q1 2017 in Review

D.E. Shaw & Co sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2017, closing a stake of 1,995 shares — an estimated $196K sold.

D.E. Shaw & Co first reported a position in ARGS in Q4 2016 and held it in 1 quarter. The position peaked at $196K in Q4 2016. 43 funds tracked by Wall St. Rank hold ARGS as of Q1 2017.

D.E. Shaw & Co reported no remaining Argos Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
D.E. Shaw & Co sold 1,995 Argos Therapeutics, Inc. shares in Q1 2017, an estimated $196K.
D.E. Shaw & Co first reported a position in Argos Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
D.E. Shaw & Co's Argos Therapeutics, Inc. position peaked at $196K in Q4 2016.
43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2017.

Based on D.E. Shaw & Co's 13F filing for Q1 2017, filed 15 May 2017.